Peptora Get app
← All peptides

Tesamorelin

★ 75 FDA approved

Tesamorelin (Egrifta)

GHRH analog targeting visceral fat

Fat Loss
Half-life
~26-38 min, but effects sustained
Route
SubQ
Cycle
16-26 weeks on,
Status
FDA approved 2010 for HIV-associated lipodystrophy

About

FDA-approved GHRH analog, used in HIV lipodystrophy. Highly effective for visceral fat reduction.

Mechanism

GHRH analog with a longer half-life, stimulating the GH/IGF-1 axis.

Dosage

beginner

Amount
1 mg
Frequency
1x per day before sleep
Route
SubQ
Duration
12 weeks

standard

Amount
2 mg
Frequency
1x per day before sleep
Route
SubQ
Duration
16-26 weeks

advanced

Amount
2 mg + 1 mg AM
Frequency
Split into two doses
Route
SubQ
Duration
26 weeks
Timing

On an empty stomach before sleep (30-60 min prior).

Cycle structure

16-26 weeks on, 4-8 weeks off

Reconstitution & Storage

5 mg + 2.5 mL → 2 mg/mL

Fragile — always store refrigerated after reconstitution.

Lyophilized: refrigerated. Reconstituted: 2-8°C, 7 days.

Benefits

  • • Significant visceral fat reduction
  • • Improved lipid profile
  • • Increased IGF-1
  • • Muscle building
  • • Improved energy

Side effects

  • • Facial flushing
  • • Tingling
  • • Fluid retention
  • • Joint pain
  • • Rare: elevated blood glucose

Contraindications

  • • Pituitary disease
  • • Active cancer
  • • Pregnancy
  • • Diabetes (requires monitoring)

Gender notes

Men

Same dose. Best for middle-age belly fat.

Women

Same dose, 1-2 mg. Highly effective for post-menopausal belly fat.

Research

Stacks well with

IPAMORELIN BPC-157

Track Tesamorelin doses in the app

Built-in reconstitution calculator, dose log, and reminders. Free on Android.

Get on Google Play

Educational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.